Odylia Therapeutics is a nonprofit organization working to bring treatment for rare eye diseases from the lab into phase I/II clinical trials using AAV and other genetic therapies. There is pre-clinical proof-of-concept for treatments for more than 30 Inherited Retinal Diseases (IRD), with more being discovered every day. Because these diseases are so rare, there is little commercial interest, leaving us to find a way to move these potential therapies into clinical trials to prevent blindness. Odylia’s strategy is to change the paradigm for moving rare disease treatments to the clinic. By using our non-profit status as a resource, we provide an opportunity for significant discounts, efficiencies and economies of scale from a typical commercial sponsor.